pralsetinib

Action and Spectrum

Drug Interaction

Adverse Reaction

>10%: 

Increased creatinine  

Increased alkaline phosphatase  

Constipation 

Fatigue  

Musculoskeletal pain  

Decreased calcium  

Hypertension  

Cough  

Pyrexia  

Edema  

Pneumonia  

Dry mouth  

1-10%: 

Decreased phosphate  

Fatigue  

Diarrhea  

Increased AST  

Increased ALT  

Decreased platelets  

Cough  

Increased potassium  

Increased bilirubin  

Increased alkaline phosphatase 

<1%: 

Musculoskeletal pain  

Constipation  

Abdominal pain  

Stomatitis  

Nausea  

Dizziness 

Black Box Warning

Contraindication / Caution

Pralsetinib is contraindicated in patients hypersensitive to the active ingredient. 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding any fetal defects caused due to drug intake during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of the drug in breast milk. 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.        
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women        
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.        
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.        
• Category N: There is no data available for the drug under this category 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: pralsetinib 

Pronounced: pral-SEH-tih-nib 

Why do we use pralsetinib? 

Pralsetinib is a Receptor Tyrosine Kinase Inhibitor. It is used to treat Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Thyroid Cancer.